000309657 001__ 309657
000309657 005__ 20260205152952.0
000309657 0247_ $$2doi$$a10.1038/s41591-025-04079-7
000309657 0247_ $$2pmid$$apmid:41639379
000309657 0247_ $$2ISSN$$a1078-8956
000309657 0247_ $$2ISSN$$a1546-170X
000309657 037__ $$aDKFZ-2026-00289
000309657 041__ $$aEnglish
000309657 082__ $$a610
000309657 1001_ $$00000-0001-5090-8189$$aBesse, Benjamin$$b0
000309657 245__ $$aRepotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.
000309657 260__ $$a[New York, NY]$$bSpringer Nature$$c2026
000309657 3367_ $$2DRIVER$$aarticle
000309657 3367_ $$2DataCite$$aOutput Types/Journal article
000309657 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770301782_2393090
000309657 3367_ $$2BibTeX$$aARTICLE
000309657 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309657 3367_ $$00$$2EndNote$$aJournal Article
000309657 500__ $$a#NCTZFB9# / epub
000309657 520__ $$aEarly-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion-positive (NTRK+) solid tumors provide clinical benefit; however, resistance emerges. Repotrectinib is a next-generation ROS1/TRK TKI with a compact macrocyclic structure designed to improve durability of response. TRIDENT-1 is a registrational phase 1/2 trial assessing repotrectinib, a next-generation ROS1/TRK TKI, in adults with advanced solid tumors, including NTRK+ disease. The primary endpoint was confirmed objective response; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival and safety. Median follow-up ranged between 21.3 months and 25.7 months. In the TKI-naive cohort (n = 51; 95% confidence interval (CI)), the response rate was 59% (44-72); the median DOR was not estimable (NE); and the median PFS was 30.3 months (9.0-NE). In the TKI-pretreated cohort (n = 69; 95% CI), the response rate was 48% (36-60); the median DOR was 9.8 months (7.4-13.0); and the median PFS was 7.4 months (3.9-9.7). Of 30 TKI-pretreated patients with NTRK solvent front mutations, 16 had a response (53%; 95% CI: 34-72). Intracranial responses were observed in two of three TKI-naive patients and in four of six TKI-pretreated patients with measurable intracranial disease at baseline. Among all treated patients (n = 565), the most common any-grade treatment-related adverse event (TRAE) was dizziness (57%); most TRAEs were low grade; and 4% discontinued repotrectinib due to a TRAE. Here repotrectinib demonstrated durable systemic and intracranial responses with generally low-grade adverse events in patients with NTRK+ solid tumors, including those with previous TRK TKI treatment and solvent front mutations. These results support the use of repotrectinib to treat patients with NTRK+ solid tumors. ClinicalTrials.gov identifier: NCT03093116 .
000309657 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309657 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309657 7001_ $$00000-0001-7373-3916$$aLin, Jessica J$$b1
000309657 7001_ $$aBazhenova, Lyudmila$$b2
000309657 7001_ $$00000-0002-3023-2510$$aGoto, Koichi$$b3
000309657 7001_ $$00000-0001-7343-633X$$ade Langen, Adrianus Johannes$$b4
000309657 7001_ $$aKim, Dong-Wan$$b5
000309657 7001_ $$aWolf, Jürgen$$b6
000309657 7001_ $$00000-0003-3843-101X$$aSpringfeld, Christoph$$b7
000309657 7001_ $$00000-0003-2087-4963$$aPopat, Sanjay$$b8
000309657 7001_ $$00000-0002-4655-0206$$aLim, Darren W T$$b9
000309657 7001_ $$aNagasaka, Misako$$b10
000309657 7001_ $$aHong, Jung Yong$$b11
000309657 7001_ $$aBaik, Christina S$$b12
000309657 7001_ $$aHervieu, Alice$$b13
000309657 7001_ $$00000-0001-6099-4236$$aMoreno, Victor$$b14
000309657 7001_ $$aYang, Nong$$b15
000309657 7001_ $$aKollengode, Kanthi$$b16
000309657 7001_ $$aYang, Haisu$$b17
000309657 7001_ $$aXu, Yuanfang$$b18
000309657 7001_ $$aCalvet, Christophe Y$$b19
000309657 7001_ $$aYuan, Yong$$b20
000309657 7001_ $$aHammell, Amy B$$b21
000309657 7001_ $$00000-0001-6806-9061$$aDrilon, Alexander$$b22
000309657 7001_ $$00000-0003-3059-5730$$aSolomon, Benjamin J$$b23
000309657 773__ $$0PERI:(DE-600)1484517-9$$a10.1038/s41591-025-04079-7$$pnn$$tNature medicine$$vnn$$x1078-8956$$y2026
000309657 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-3843-101X$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000309657 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309657 9141_ $$y2026
000309657 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-06$$wger
000309657 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2025-01-06$$wger
000309657 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT MED : 2022$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-06
000309657 915__ $$0StatID:(DE-HGF)9980$$2StatID$$aIF >= 80$$bNAT MED : 2022$$d2025-01-06
000309657 9201_ $$0I:(DE-He78)HD02-20160331$$kHD02$$lKoordinierungsstelle NCT Heidelberg$$x0
000309657 980__ $$ajournal
000309657 980__ $$aVDB
000309657 980__ $$aI:(DE-He78)HD02-20160331
000309657 980__ $$aUNRESTRICTED